自己細胞治療市場：供給源、適応症、エンドユーザー別-2025-2030年の世界予測

自己細胞治療市場は、2023年に81億1,000万米ドルと評価され、2024年には92億4,000万米ドルに達すると予測され、CAGR 14.52％で成長し、2030年には209億6,000万米ドルに達すると予測されています。

自己細胞治療は、主に個別化医療において、組織や臓器の治療や再生に患者自身の細胞を使用することを含みます。こうした治療の必要性は、免疫拒絶反応を最小限に抑え、がん、心血管疾患、神経変性疾患などの治療成績を改善する可能性から高まっています。その応用範囲は、再生医療、がん治療、整形外科治療など多岐にわたる。最終用途は病院、診療所、研究機関など多岐にわたり、個別化医療や精密医療がますます優先されるようになっています。市場成長の原動力となっているのは、細胞ベースの研究の進歩、慢性疾患の有病率の上昇、細胞の挙動と操作に対する理解の深化であり、これらによって治療の革新的な道筋が開かれます。患者の転帰予測分析におけるAIと機械学習の統合は、市場の関心をさらに高める。このような機会にもかかわらず、高コスト、細胞加工に関するロジスティクスの問題、規制上のハードル、標準化された治療プロトコルの欠如といった課題が大きな制約となっています。遺伝子操作に関する倫理的な懸念や大量生産における複雑さも、シームレスな市場拡大の妨げとなっています。企業にとって、スケーラブルな製造プロセスのための研究開発への投資や凍結保存技術の向上は、新たな可能性を引き出すことができます。効率的な細胞ハンドリングやバイオインフォマティクス・ツールの増強のための自動化やロボット工学の革新は、競争上の優位性をもたらす可能性があります。バイオテクノロジー企業、学術機関、ヘルスケア・プロバイダー間の連携を促進することで、研究から臨床応用へのスムーズな移行を促すこともできます。自己細胞治療市場の性質はダイナミックで細分化されており、その動向はカスタマイズや患者に特化したソリューションに対する需要が急増していることを示しています。このようなイノベーションとコラボレーションの分野に注力することで、企業は課題を克服し、バイオテクノロジーの変革期であるこの分野で急成長するチャンスを活かすことができます。

市場力学：急速に進化する自己細胞治療市場の主要市場インサイトを公開

自己細胞治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の慢性疾患の増加
  • 新たな用途に向けた医薬品開発への注目の高まり
  • ヘルスケアインフラの改善に伴う個別化医薬品のニーズの高まり
• 市場抑制要因
  • 自己細胞治療に伴う高コスト
• 市場機会
  • 自己細胞治療の製造の分散化に向けた技術の進歩
  • 細胞ベースの研究に対する政府投資の増加
• 市場の課題
  • 長い納期と限られた保存期間に関する問題

ポーターのファイブフォース：自己細胞治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：自己細胞治療市場における外部からの影響の把握

外部マクロ環境要因は、自己細胞治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析自己細胞治療市場における競合情勢の把握

自己細胞治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス自己細胞治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、自己細胞治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨自己細胞治療市場における成功への道筋を描く

自己細胞治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で慢性疾患の発生率が上昇
    • 新たな用途に向けた医薬品開発への注力拡大
    • ヘルスケアインフラの改善に伴い、個別化医療のニーズが高まっている
  • 抑制要因
    • 自己細胞療法に伴う高コスト
  • 機会
    • 自己細胞療法の製造を分散化するための技術的進歩
    • 細胞ベースの調査への政府投資の増加
  • 課題
    • 長い処理時間と限られた保存期間に関連する問題
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 自己細胞治療市場：ソース別

• 骨髄
• 軟骨細胞
• 表皮
• 造血幹細胞
• 間葉系幹細胞

第7章 自己細胞治療市場適応症別

• 自己免疫疾患
• がん
• 心血管疾患
• 神経変性疾患
• 整形外科
• 傷の治癒

第8章 自己細胞治療市場：エンドユーザー別

• 学術機関および調査機関
• 外来手術センター
• 病院・クリニック

第9章 南北アメリカの自己細胞治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の自己細胞治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの自己細胞治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abata Therapeutics
• Achilles Therapeutics plc
• Adaptimmune Therapeutics PLC
• Adicet Bio Inc.
• AIVITA Biomedical, Inc.
• Aspen Neuroscienc Inc.
• Bellicum Phamaceuticals, Inc.
• BioLineRx Ltd.
• BioSpace, Inc.
• BrainStorm Cell Limited.
• Bristol-Myers Squibb Company
• Carisma Therapeutics Inc.
• Catalent, Inc.
• Cell Therapy Catapult Ltd.
• Fate Therapeutics Inc.
• GentiBio, Inc.
• IASO BioTherapeutics
• Kyverna Therapeutics, Inc.
• NOVADIP Biosciences S.A.
• Orchard Therapeutics Inc.
• T-knife Therapeutics, Inc.
• ThermoGenesis Holdings, Inc.
• Triumvira Immunologics Inc.
• Vita Therapeutics, Inc.

LIST OF FIGURES

• FIGURE 1. AUTOLOGOUS CELL THERAPIES MARKET RESEARCH PROCESS
• FIGURE 2. AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. AUTOLOGOUS CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. AUTOLOGOUS CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. AUTOLOGOUS CELL THERAPIES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. AUTOLOGOUS CELL THERAPIES MARKET DYNAMICS
• TABLE 7. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CHONDROCYTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY EPIDERMIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HAEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMICS & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 35. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 36. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. AUSTRALIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 52. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 53. CHINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 55. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. INDIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. INDONESIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 62. JAPAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. MALAYSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. PHILIPPINES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. SINGAPORE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 74. SOUTH KOREA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 77. TAIWAN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. THAILAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. VIETNAM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 90. DENMARK AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 93. EGYPT AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. FINLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 102. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 105. ISRAEL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 107. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 108. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. NETHERLANDS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 114. NIGERIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. NORWAY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. POLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 119. POLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. POLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. QATAR AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 122. QATAR AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 123. QATAR AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 126. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 138. SWEDEN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. SWITZERLAND AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. TURKEY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 150. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. AUTOLOGOUS CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 152. AUTOLOGOUS CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023

The Autologous Cell Therapies Market was valued at USD 8.11 billion in 2023, expected to reach USD 9.24 billion in 2024, and is projected to grow at a CAGR of 14.52%, to USD 20.96 billion by 2030.

Autologous Cell Therapies involve using a patient's own cells for the treatment and regeneration of tissues and organs, primarily in personalized medicine. The necessity for these therapies grows from their potential to minimize immune rejection and improve treatment outcomes for conditions like cancer, cardiovascular disorders, and neurodegenerative diseases. Their application spans across regenerative medicine, cancer therapies, orthopedic treatments, and beyond. The end-use scope is significant across hospitals, clinics, and research institutes, where personalized and precision medicine is increasingly prioritized. Market growth is driven by advancements in cell-based research, escalating prevalence of chronic diseases, and an enhanced understanding of cell behavior and manipulation, which open up innovative pathways for treatment. The integration of AI and machine learning in predictive analytics for patient outcomes further propels market interest. Despite these opportunities, challenges such as high costs, logistical issues with cell processing, regulatory hurdles, and a lack of standardized treatment protocols pose significant limitations. Ethical concerns about genetic manipulation and complexities in large-scale production also deter seamless market expansion. For businesses, investing in R&D for scalable manufacturing processes and improving cryopreservation techniques can unlock new possibilities. Innovations in automation and robotics for efficient cell handling and augmentation of bioinformatics tools could offer competitive advantages. Encouraging collaborations between biotech firms, academic institutions, and healthcare providers can also facilitate smoother transitions from research to clinical applications. The nature of the autologous cell therapy market is dynamic and segmented, with trends indicating a surging demand for customization and patient-specific solutions. By focusing on these areas of innovation and collaboration, companies can better position themselves to navigate challenges and capitalize on the burgeoning opportunities within this transformative sector of biotechnology.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Autologous Cell Therapies Market

The Autologous Cell Therapies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rise in incidences of chronic diseases worldwide
  • Expanding focus on drug development for new applications
  • Growing need for personalized medicines with improving healthcare infrastructure
• Market Restraints
  • High cost associated with autologous cell therapy
• Market Opportunities
  • Technological advancements for decentralizing manufacturing of autologous cell therapy
  • Rising government investments in cell-based research
• Market Challenges
  • Problems associated with long turnaround time and limited shelf life

Porter's Five Forces: A Strategic Tool for Navigating the Autologous Cell Therapies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Autologous Cell Therapies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Autologous Cell Therapies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Autologous Cell Therapies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Autologous Cell Therapies Market

A detailed market share analysis in the Autologous Cell Therapies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Autologous Cell Therapies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Autologous Cell Therapies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Autologous Cell Therapies Market

A strategic analysis of the Autologous Cell Therapies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Autologous Cell Therapies Market, highlighting leading vendors and their innovative profiles. These include Abata Therapeutics, Achilles Therapeutics plc, Adaptimmune Therapeutics PLC, Adicet Bio Inc., AIVITA Biomedical, Inc., Aspen Neuroscienc Inc., Bellicum Phamaceuticals, Inc., BioLineRx Ltd., BioSpace, Inc., BrainStorm Cell Limited., Bristol-Myers Squibb Company, Carisma Therapeutics Inc., Catalent, Inc., Cell Therapy Catapult Ltd., Fate Therapeutics Inc., GentiBio, Inc., IASO BioTherapeutics, Kyverna Therapeutics, Inc., NOVADIP Biosciences S.A., Orchard Therapeutics Inc., T-knife Therapeutics, Inc., ThermoGenesis Holdings, Inc., Triumvira Immunologics Inc., and Vita Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Autologous Cell Therapies Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Source, market is studied across Bone Marrow, Chondrocytes, Epidermis, Haematopoietic Stem Cells, and Mesenchymal Stem Cells.
• Based on Indication, market is studied across Autoimmune Disorders, Cancer, Cardiovascular Disorders, Neurodegenerative Disorders, Orthopedics, and Wound Healing.
• Based on End-User, market is studied across Academics & Research Institutes, Ambulatory Surgical Centers, and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in incidences of chronic diseases worldwide
    • 5.1.1.2. Expanding focus on drug development for new applications
    • 5.1.1.3. Growing need for personalized medicines with improving healthcare infrastructure
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with autologous cell therapy
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements for decentralizing manufacturing of autologous cell therapy
    • 5.1.3.2. Rising government investments in cell-based research
  • 5.1.4. Challenges
    • 5.1.4.1. Problems associated with long turnaround time and limited shelf life
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Autologous Cell Therapies Market, by Source

• 6.1. Introduction
• 6.2. Bone Marrow
• 6.3. Chondrocytes
• 6.4. Epidermis
• 6.5. Haematopoietic Stem Cells
• 6.6. Mesenchymal Stem Cells

7. Autologous Cell Therapies Market, by Indication

• 7.1. Introduction
• 7.2. Autoimmune Disorders
• 7.3. Cancer
• 7.4. Cardiovascular Disorders
• 7.5. Neurodegenerative Disorders
• 7.6. Orthopedics
• 7.7. Wound Healing

8. Autologous Cell Therapies Market, by End-User

• 8.1. Introduction
• 8.2. Academics & Research Institutes
• 8.3. Ambulatory Surgical Centers
• 8.4. Hospitals & Clinics

9. Americas Autologous Cell Therapies Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Autologous Cell Therapies Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Autologous Cell Therapies Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abata Therapeutics
• 2. Achilles Therapeutics plc
• 3. Adaptimmune Therapeutics PLC
• 4. Adicet Bio Inc.
• 5. AIVITA Biomedical, Inc.
• 6. Aspen Neuroscienc Inc.
• 7. Bellicum Phamaceuticals, Inc.
• 8. BioLineRx Ltd.
• 9. BioSpace, Inc.
• 10. BrainStorm Cell Limited.
• 11. Bristol-Myers Squibb Company
• 12. Carisma Therapeutics Inc.
• 13. Catalent, Inc.
• 14. Cell Therapy Catapult Ltd.
• 15. Fate Therapeutics Inc.
• 16. GentiBio, Inc.
• 17. IASO BioTherapeutics
• 18. Kyverna Therapeutics, Inc.
• 19. NOVADIP Biosciences S.A.
• 20. Orchard Therapeutics Inc.
• 21. T-knife Therapeutics, Inc.
• 22. ThermoGenesis Holdings, Inc.
• 23. Triumvira Immunologics Inc.
• 24. Vita Therapeutics, Inc.